Healthcare provider profile · identity verified

Douglas E Leaman, M.D.

Family Practice · LANCASTER, PA · NPI 1295866119

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	183	45
Metformin Hcl	Metformin Hcl	181	39
Trulicity	Dulaglutide	130	19
Lisinopril	Lisinopril	129	33
Omeprazole	Omeprazole	128	34
Gabapentin	Gabapentin	126	23
Albuterol Sulfate Hfa	Albuterol Sulfate	125	25
Amlodipine Besylate	Amlodipine Besylate	121	36
Jardiance	Empagliflozin	106	26
Fluoxetine Hcl	Fluoxetine Hcl	84	18
Metoprolol Succinate	Metoprolol Succinate	84	19
Fluticasone Propionate	Fluticasone Propionate	83	32
Levothyroxine Sodium	Levothyroxine Sodium	81	17
Tamsulosin Hcl	Tamsulosin Hcl	68	22
Losartan Potassium	Losartan Potassium	62	20
Hydroxyzine Hcl	Hydroxyzine Hcl	58	16
Diclofenac Sodium	Diclofenac Sodium	49	17
Famotidine	Famotidine	45	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	44	suppressed
Mirtazapine	Mirtazapine	42	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	38	suppressed
Naproxen	Naproxen	37	suppressed
Trazodone Hcl	Trazodone Hcl	36	suppressed
Ozempic	Semaglutide	35	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	35	suppressed
Sertraline Hcl	Sertraline Hcl	34	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	33	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	31	suppressed
Clopidogrel	Clopidogrel Bisulfate	30	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	30	11
Montelukast Sodium	Montelukast Sodium	30	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	30	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	28	suppressed
Nitroglycerin	Nitroglycerin	27	suppressed
Ondansetron Odt	Ondansetron	26	suppressed
Promethazine Hcl	Promethazine Hcl	24	suppressed
Eliquis	Apixaban	23	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	23	suppressed
Oxycodone Hcl	Oxycodone Hcl	22	suppressed
Pregabalin	Pregabalin	22	suppressed
Nifedipine Er	Nifedipine	21	suppressed
Simvastatin	Simvastatin	21	suppressed
Finasteride	Finasteride	20	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	20	suppressed
Januvia	Sitagliptin Phosphate	20	suppressed
Furosemide	Furosemide	19	suppressed
Carvedilol	Carvedilol	18	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	18	suppressed
Ibuprofen	Ibuprofen	18	suppressed
Pravastatin Sodium	Pravastatin Sodium	18	suppressed
Topiramate	Topiramate	18	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	17	suppressed
Bydureon Bcise	Exenatide Microspheres	17	suppressed
Farxiga	Dapagliflozin Propanediol	17	suppressed
Paroxetine Hcl	Paroxetine Hcl	17	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	17	suppressed
Qvar Redihaler	Beclomethasone Dipropionate	16	suppressed
Buspirone Hcl	Buspirone Hcl	15	suppressed
Clotrimazole	Clotrimazole	15	suppressed
Donepezil Hcl	Donepezil Hcl	15	suppressed
Doxepin Hcl	Doxepin Hcl	15	suppressed
Meclizine Hcl	Meclizine Hcl	15	suppressed
Warfarin Sodium	Warfarin Sodium	15	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	14	suppressed
Duloxetine Hcl	Duloxetine Hcl	14	suppressed
Lidocaine-Prilocaine	Lidocaine/Prilocaine	14	suppressed
Novolog Flexpen	Insulin Aspart	14	suppressed
Entresto	Sacubitril/Valsartan	13	suppressed
Ezetimibe	Ezetimibe	13	suppressed
Humalog Kwikpen U-100	Insulin Lispro	13	suppressed
Loperamide	Loperamide Hcl	13	suppressed
Lyrica	Pregabalin	13	suppressed
Irbesartan	Irbesartan	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Allopurinol	Allopurinol	11	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	11	suppressed
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	11	suppressed
Latanoprost	Latanoprost	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error